我们所展示的质粒图谱主要是从文献和开放数据库中收集而来,主要是为了方便研究工作,其中一小部分质粒进行了质量控制,可供科学家使用。
所有的产品都严格仅供科学研究使用,不能应用于临床试验,包括人体摄入、注射或外用的药理学用途。
确保质粒的关键元件正确,但是我们并不能保证实验结果。页面展示的图谱序列为理论序列,可能与测序结果不一致,请自行比对后确定是否满足要求。(如果测过序,本页面一般会提供下载)
开放数据库中的大多数载体序列都没有被完全测序。如果实际序列与参考序列的相似度超过99%,则将其视为正确。
由于科学研究是在探索未知,具有很大的不确定性,在任何情况下,我们都不承担超出质粒本身的额外经济损失或责任。
This is a mammalian expression with Myc-Flag, a dual tagging vector. It serves as an entry vector to transfer an ORF into a destination vector.
- 载体名称:
- pCMV6-Entry
- 载体抗性:
- Kanamycin
- 载体长度:
- 4919 bp
- 载体类型:
- Mammalian Expression Vectors
- 复制子:
- ori
- 载体来源:
- OriGene
- 筛选标记:
- Neomycin/G418(Geneticin)
- 拷贝数:
- High copy number
- 启动子:
- SV40
pCMV6-Entry 载体图谱
质粒操作方法
1. 发货形式:质粒干粉(常温运输,存于-20度,请务必先转化提质粒后使用)
2. 收到质粒干粉后请先5000rpm离心1min,再加入20μl ddH2O溶解质粒;(质粒复测的浓度有时候与标称值差距较大,这可能是因为冻干质粒在管中的位置、复溶效率、测量偏差以及管壁的吸附导致,因此建议先转化提质粒后再使用)
3. 取1支100μl 感受态于冰上解冻10min,加入2μl质粒,再冰浴30min后,42℃热激60s,不要搅动,再冰浴2min;
4. 加入900μl无抗的LB液体培养基,180rpm震荡37℃培养45min (30℃培养1-1.5小时);
5. 6000rpm离心5min,仅留100μl上清液重悬细菌沉淀,并涂布至目标质粒抗性的LB平板上;
6. 将平板倒置37℃培养14h,如果要求是30℃则培养20h; (菌落过多则将质粒稀释后再转化;没有菌落则加入10μl质粒转化;建议不要直接转表达感受态, 要先转克隆感受态,重提质粒后再导入表达感受态);
7. 挑取单菌落至LB液体培养基中,加入对应抗生素,220rpm震荡培养14h,根据实验需要和质粒提取试剂盒说明书提取质粒。
pCMV6-Entry 载体序列
LOCUS pCMV6-Entry. 4919 bp DNA circular SYN 01-JAN-1980
DEFINITION Mammalian expression and dual tagging vector that serves as an entry
vector to transfer an ORF into a destination vector using the
PrecisionShuttle(TM) system.
ACCESSION .
VERSION .
KEYWORDS pCMV6-Entry
SOURCE synthetic DNA construct
ORGANISM synthetic DNA construct
REFERENCE 1 (bases 1 to 4919)
AUTHORS OriGene
TITLE Direct Submission
REFERENCE 2 (bases 1 to 4919)
AUTHORS .
TITLE Direct Submission
COMMENT SGRef: number: 1; type: "Journal Article"
COMMENT Inserts are cloned between the SgfI (AsiSI) and MluI sites.
FEATURES Location/Qualifiers
source 1..4919
/mol_type="other DNA"
/organism="synthetic DNA construct"
primer_bind 166..182
/label=M13 fwd
/note="common sequencing primer, one of multiple similar
variants"
enhancer 343..722
/label=CMV enhancer
/note="human cytomegalovirus immediate early enhancer"
promoter 723..926
/label=CMV promoter
/note="human cytomegalovirus (CMV) immediate early
promoter"
promoter 952..970
/label=T7 promoter
/note="promoter for bacteriophage T7 RNA polymerase"
misc_feature 979..1087
/label=MCS
/note="MCS"
/note="multiple cloning site"
CDS 1085..1114
/label=Myc
/note="Myc (human c-Myc proto-oncogene) epitope tag"
CDS 1133..1156
/label=FLAG
/note="FLAG(R) epitope tag, followed by an enterokinase
cleavage site"
primer_bind complement(1176..1192)
/label=M13 rev
/note="common sequencing primer, one of multiple similar
variants"
polyA_signal 1203..1825
/label=hGH poly(A) signal
/note="human growth hormone polyadenylation signal"
rep_origin complement(1974..2562)
/direction=LEFT
/label=ori
/note="high-copy-number ColE1/pMB1/pBR322/pUC origin of
replication"
polyA_signal complement(2891..2938)
/label=HSV TK poly(A) signal
/note="herpes simplex virus thymidine kinase
polyadenylation signal (Cole and Stacy, 1985)"
CDS complement(3173..3964)
/label=NeoR/KanR
/note="aminoglycoside phosphotransferase"
promoter complement(3999..4356)
/label=SV40 promoter
/note="SV40 enhancer and early promoter"
promoter complement(4358..4462)
/label=AmpR promoter
rep_origin 4489..4919
/label=f1 ori
/note="f1 bacteriophage origin of replication; arrow
indicates direction of (+) strand synthesis"